메뉴 건너뛰기




Volumn 178, Issue 1, 2018, Pages 114-123

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; APREMILAST; CYCLOSPORINE; ETANERCEPT; ETRETIN; GUSELKUMAB; INFLIXIMAB; METHOTREXATE; TOFACITINIB; USTEKINUMAB; BIOLOGICAL PRODUCT; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

EID: 85028508389     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.15750     Document Type: Article
Times cited : (272)

References (23)
  • 1
    • 84872620069 scopus 로고    scopus 로고
    • Global epidemiology of psoriasis: a systematic review of incidence and prevalence
    • Parisi R, Symmons DP, Griffiths CE et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133:377–85.
    • (2013) J Invest Dermatol , vol.133 , pp. 377-385
    • Parisi, R.1    Symmons, D.P.2    Griffiths, C.E.3
  • 2
    • 33847279025 scopus 로고    scopus 로고
    • Pathogenesis and therapy of psoriasis
    • Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445:866–73.
    • (2007) Nature , vol.445 , pp. 866-873
    • Lowes, M.A.1    Bowcock, A.M.2    Krueger, J.G.3
  • 3
    • 63149104648 scopus 로고    scopus 로고
    • Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis
    • Yawalkar N, Tscharner GG, Hunger RE, Hassan AS. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J Dermatol Sci 2009; 54:99–105.
    • (2009) J Dermatol Sci , vol.54 , pp. 99-105
    • Yawalkar, N.1    Tscharner, G.G.2    Hunger, R.E.3    Hassan, A.S.4
  • 4
    • 84922410788 scopus 로고    scopus 로고
    • Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis
    • Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol 2015; 27:127–33.
    • (2015) Curr Opin Rheumatol , vol.27 , pp. 127-133
    • Mease, P.J.1
  • 5
    • 58749105841 scopus 로고    scopus 로고
    • IL-23 promotes maintenance but not commitment to the Th17 lineage
    • Stritesky GL, Yeh N, Kaplan MH. IL-23 promotes maintenance but not commitment to the Th17 lineage. J Immunol 2008; 181:5948–55.
    • (2008) J Immunol , vol.181 , pp. 5948-5955
    • Stritesky, G.L.1    Yeh, N.2    Kaplan, M.H.3
  • 6
    • 43449111187 scopus 로고    scopus 로고
    • Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
    • Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371:1665–74.
    • (2008) Lancet , vol.371 , pp. 1665-1674
    • Leonardi, C.L.1    Kimball, A.B.2    Papp, K.A.3
  • 7
    • 43449139402 scopus 로고    scopus 로고
    • Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
    • Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371:1675–84.
    • (2008) Lancet , vol.371 , pp. 1675-1684
    • Papp, K.A.1    Langley, R.G.2    Lebwohl, M.3
  • 8
    • 85008701919 scopus 로고    scopus 로고
    • Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial
    • Blauvelt A, Papp KA, Griffiths CE et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 2017; 76:405–17.
    • (2017) J Am Acad Dermatol , vol.76 , pp. 405-417
    • Blauvelt, A.1    Papp, K.A.2    Griffiths, C.E.3
  • 9
    • 84938992082 scopus 로고    scopus 로고
    • Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
    • Griffiths CE, Reich K, Lebwohl M et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015; 386:541–51.
    • (2015) Lancet , vol.386 , pp. 541-551
    • Griffiths, C.E.1    Reich, K.2    Lebwohl, M.3
  • 10
    • 84904545875 scopus 로고    scopus 로고
    • Secukinumab in plaque psoriasis–results of two phase 3 trials
    • Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med 2014; 371:326–38.
    • (2014) N Engl J Med , vol.371 , pp. 326-338
    • Langley, R.G.1    Elewski, B.E.2    Lebwohl, M.3
  • 11
    • 84942876148 scopus 로고    scopus 로고
    • Phase 3 studies comparing brodalumab with ustekinumab in psoriasis
    • Lebwohl M, Strober B, Menter A et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015; 373:1318–28.
    • (2015) N Engl J Med , vol.373 , pp. 1318-1328
    • Lebwohl, M.1    Strober, B.2    Menter, A.3
  • 12
    • 85008601511 scopus 로고    scopus 로고
    • Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial
    • Reich K, Armstrong AW, Foley P et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 2017; 76:418–31.
    • (2017) J Am Acad Dermatol , vol.76 , pp. 418-431
    • Reich, K.1    Armstrong, A.W.2    Foley, P.3
  • 13
    • 84977071601 scopus 로고    scopus 로고
    • Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis
    • Gordon KB, Blauvelt A, Papp KA et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med 2016; 375:345–56.
    • (2016) N Engl J Med , vol.375 , pp. 345-356
    • Gordon, K.B.1    Blauvelt, A.2    Papp, K.A.3
  • 14
    • 84994735189 scopus 로고    scopus 로고
    • Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study
    • e9
    • Blauvelt A, Reich K, Tsai TF et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol 2017; 76:60–69.e9. https://doi.org/10.1016/j.jaad.2016.08.008
    • (2017) J Am Acad Dermatol , vol.76 , pp. 60-69
    • Blauvelt, A.1    Reich, K.2    Tsai, T.F.3
  • 15
    • 84936763292 scopus 로고    scopus 로고
    • A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis
    • Gordon KB, Duffin KC, Bissonnette R et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis. N Engl J Med 2015; 373:136–44.
    • (2015) N Engl J Med , vol.373 , pp. 136-144
    • Gordon, K.B.1    Duffin, K.C.2    Bissonnette, R.3
  • 16
    • 0018099294 scopus 로고
    • Severe psoriasis–oral therapy with a new retinoid
    • Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica 1978; 157:238–44.
    • (1978) Dermatologica , vol.157 , pp. 238-244
    • Fredriksson, T.1    Pettersson, U.2
  • 17
    • 84924340693 scopus 로고    scopus 로고
    • The 5-point Investigator's Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials
    • Langley RG, Feldman SR, Nyirady J et al. The 5-point Investigator's Global Assessment (IGA) Scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat 2016; 26:23–31.
    • (2016) J Dermatolog Treat , vol.26 , pp. 23-31
    • Langley, R.G.1    Feldman, S.R.2    Nyirady, J.3
  • 18
    • 0028332995 scopus 로고
    • Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use
    • Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210–16.
    • (1994) Clin Exp Dermatol , vol.19 , pp. 210-216
    • Finlay, A.Y.1    Khan, G.K.2
  • 19
    • 84949198562 scopus 로고    scopus 로고
    • Measurement properties of a patient-reported outcome measure assessing psoriasis severity: the psoriasis symptoms and signs diary
    • Mathias SD, Feldman SR, Crosby RD et al. Measurement properties of a patient-reported outcome measure assessing psoriasis severity: the psoriasis symptoms and signs diary. J Dermatolog Treat 2016; 27:322–7.
    • (2016) J Dermatolog Treat , vol.27 , pp. 322-327
    • Mathias, S.D.1    Feldman, S.R.2    Crosby, R.D.3
  • 21
    • 84883134297 scopus 로고    scopus 로고
    • Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
    • McInnes IB, Kavanaugh A, Gottlieb AB et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013; 382:780–9.
    • (2013) Lancet , vol.382 , pp. 780-789
    • McInnes, I.B.1    Kavanaugh, A.2    Gottlieb, A.B.3
  • 22
    • 84958043348 scopus 로고    scopus 로고
    • Patient-relevant treatment goals in psoriasis
    • Blome C, Gosau R, Radtke MA et al. Patient-relevant treatment goals in psoriasis. Arch Dermatol Res 2016; 308:69–78.
    • (2016) Arch Dermatol Res , vol.308 , pp. 69-78
    • Blome, C.1    Gosau, R.2    Radtke, M.A.3
  • 23
    • 84971333765 scopus 로고    scopus 로고
    • Clinical meaningfulness of complete skin clearance in psoriasis
    • e7
    • Strober B, Papp KA, Lebwohl M et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol 2016; 75:77–82.e7.
    • (2016) J Am Acad Dermatol , vol.75 , pp. 77-82
    • Strober, B.1    Papp, K.A.2    Lebwohl, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.